Cidara TherapeuticsCidara Therapeutics expands partnership with WuXi XDC

02 Feb 2023
www.pharmaceutical-technology.com
Cidara Therapeutics expands partnership with WuXi XDC
Preview
Source: Pharmaceutical Technology
CD421 is CidaraCidara’s lead oncology candidate. Credit: National Cancer Institute on Unsplash.
Cidara Therapeutics has announced the expansion of its existing collaboration with WuXi XDC for advancing the CD73 oncology DFC programme.
The deal builds on the existing partnership with WuXi XDC for chemistry, manufacturing, and controls (CMC) development and GMP manufacturing services for the CD388 influenza drug-Fc conjugate (DFC) programme of Cidara.
Under the latest deal, WuXi XDC will be responsible for providing investigational new drug (IND)-enabling CMC development services for Cidara’s lead CD73 oncology DFC programme.
Cidara Therapeutics president and CEO Jeff Stein said: “WuXi XDC has been an excellent development and manufacturing partner for our ongoing CD388 influenza DFC programme, and we are excited to expand this relationship by combining WuXi XDC’s core competencies in bioconjugates manufacturing with our expertise in DFCs to advance the manufacturing of our first-in-class CD73 oncology DFC.”
CD421, the company’s lead oncology candidate, works by targeting CD73 in the adenosine pathway that contributes to immune evasion in solid cancers.
Cidara stated that CD73 is extremely expressed on many tumour and stromal cells and immunosuppressive cells, including myeloid-derived suppressor cells and regulatory T cells.
The CD73 DFC has been designed for addressing the pharmacokinetic, safety, efficacy, and potency limitations of small molecule and monoclonal antibody candidates that target CD73.
WuXi XDC CEO Dr Jimmy Li said: “This expanded partnership is a strong testament to our industry-leading capabilities and expertise.
“We’re committed to building an innovation ecosystem for bioconjugates by offering global open-access technology platforms with premier quality standards to support our partners worldwide as they build their innovative ideas into transformative new treatments for patients.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.